Revance to Present Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Fillers at American Academy of Dermatology VMX Meeting 2021
Revance Therapeutics, a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that it will present four ePoster abstracts at the virtual American Academy of Dermatology (AAD VMX) meeting, April 23-25, 2021, including new data from the SAKURA Phase 3 clinical program for DaxibotulinumtoxinA for Injection, the company’s investigational, next-generation neuromodulator. The company will showcase new results on the elimination of glabellar lines following treatment with DaxibotulinumtoxinA for Injection, made evident through a novel approach visualizing the entire distribution of glabellar line severity ratings in the depiction of efficacy.
A second ePoster will highlight data from a subgroup analysis on the efficacy, duration and safety of DaxibotulinumtoxinA for Injection among adult female subjects across multiple age cohorts from the SAKURA Phase 3 program, and a third ePoster will include results from an evaluation of the progressive effects on static/resting glabellar lines with the repeated treatment of DaxibotulinumtoxinA for Injection. A fourth ePoster will highlight results from a study evaluating the impact of hyaluronic acid (HA) filler manufacturing technologies on HA chain degradation.
“We look forward to sharing new data from our SAKURA Phase 3 program with the aesthetic community at AAD VMX, as well as highlighting study results of our hyaluronic acid fillers manufacturing technology,” said Roman Rubio, Senior Vice President of Clinical Development at Revance. “These data continue to underscore the innovation that drives Revance’s aesthetics portfolio, including our investigational neuromodulator product, DaxibotulinumtoxinA for Injection, and the RHA Collection, which was launched in September 2020.”
The abstracts are available online via the AAD VMX website at www.aad.org. Attendees can access all of the sessions on-demand through July 12, 2021.
Abstracts to be presented at AAD:
Title: Visualizing the Elimination of Glabellar Lines Following Treatment with DaxibotulinumtoxinA for Injection (DAXI)
Authors and Affiliations: Shannon Humphrey, Humphrey Cosmetic Dermatology, Vancouver, British Columbia, Canada, Sabrina Fabi, Cosmetic Laser Dermatology, San Diego, CA, USA, Derek Jones, Skin Care and Laser Physicians of Beverly Hills, Beverly Hills, CA, USA, Todd Gross, Yan Liu, Roman Rubio, Revance Therapeutics, Inc., Newark, CA, USA
Title: DaxibotulinumtoxinA for Injection (DAXI)–treated Subjects Show Progressive Improvement in Static Glabellar Lines With Repeated Treatment